Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects.

Clinical pharmacology in drug development - 1 Jan 2015

Finkelman Richard D, Wang Tzung-Dau, Wang Yi, Azumaya Connie T, Birmingham Bruce K, Wissmar Jenny, Mosqueda-Garcia Rogelio

Abstract excerpt

CYP2C19 contributes to N-desmethyl rosuvastatin formation in "in vitro" models. Approximately 80% of Taiwanese are CYP2C19 extensive metabolizers (EMs, CYP2C19*1/*1, *1/*2, or *1/*3). We studied the potential effect of CYP2C19 genotypes on rosuvastatin pharmacokinetics in healthy Taiwanese subjects following single and multiple daily oral doses of rosuvastatin calcium (20 mg). Geometric mean ratios for poor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Biotransformation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Healthy Volunteers

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Pharmacogenomic Testing

Share to Pharmacogenomic Variants

Share to Rosuvastatin Calcium

Source

Identifiers

PMID: 27128002
DOI: 10.1002/cpdd.135

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects.PMID 27128002Read ↗

No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.Semantic proximity Read ↗

Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.Semantic proximity Read ↗

ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.Semantic proximity Read ↗

The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.Semantic proximity Read ↗

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.Semantic proximity Read ↗

CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy.Semantic proximity Read ↗

Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.Semantic proximity Read ↗

Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.Semantic proximity Read ↗

Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects.Semantic proximity Read ↗

Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions.Semantic proximity Read ↗

CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.Semantic proximity Read ↗

Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.